Cediranib Maleate clinical trials
Cediranib Maleate is named as an intervention in 10 current clinical trials in our Canada, Israel, Mexico, South Korea, Japan, Egypt, UK, USA, Germany, France, Spain and Austria registers. None are recruiting at the moment. The most common phase is Phase 2. The sponsor with the most trials is National Cancer Institute (NCI) (7). The most-studied condition is Fallopian Tube Clear Cell Adenocarcinoma.
Where Cediranib Maleate is approved
All regulators →- 1 EU orphan designation, most recently for treatment of ovarian cancer (29 Jul 2014, positive)
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
How Cediranib Maleate works
All drug targets →- Inhibits KIT Primary targetTarget: KIT KIT proto-oncogene, receptor tyrosine kinaseGuide to Pharmacology only
- Inhibits PDGFRA Primary targetTarget: PDGFRA platelet derived growth factor receptor alphaGuide to Pharmacology only
- Inhibits FLT1 Primary targetTarget: FLT1 fms related receptor tyrosine kinase 1Guide to Pharmacology only
- Inhibits FLT4 Primary targetTarget: FLT4 fms related receptor tyrosine kinase 4Guide to Pharmacology only
- Inhibits KDR Primary targetTarget: KDR kinase insert domain receptorGuide to Pharmacology only
- Inhibits PDGFRB Primary targetTarget: PDGFRB platelet derived growth factor receptor betaGuide to Pharmacology only
- Fallopian tube cancerPhase 2/3
- Non-small cell lung carcinomaPhase 2/3
- Ovarian cancerPhase 2/3
- Primary peritoneal carcinomaPhase 2/3
- B-cell chronic lymphocytic leukemiaPhase 2
- Acute myeloid leukemiaPhase 2
- Breast cancerPhase 2
- Cervical cancerPhase 2
- Endometrial cancerPhase 2
- Endometrial carcinomaPhase 2
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL2103798, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 5664, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Cediranib Maleate
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Cediranib Maleate
- ChEMBL
- CHEMBL2103798
- PubChem CID
- 11226834
- CAS number
- 857036-77-2
- FDA UNII
- 68AYS9A614
- Wikidata
- Q27264241
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of Cediranib Maleate
10 trialsRegisters list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with Cediranib Maleate
31 conditionsAll 31 conditions
| Condition (as registered) | Trials |
|---|---|
| Fallopian Tube Clear Cell Adenocarcinoma | 2 |
| Fallopian Tube Transitional Cell Carcinoma | 2 |
| Solid Tumors | 1 |
| Non-Small Cell Lung Cancer | 1 |
| Mismatch Repair Proficient Colorectal Cancer | 1 |
| Pancreatic Adenocarcinoma | 1 |
| Leiomyosarcoma | 1 |
| Fallopian Tube Endometrioid Adenocarcinoma | 1 |
| Fallopian Tube Serous Adenocarcinoma | 1 |
| Advanced Prostate Adenocarcinoma With Neuroendocrine Differentiation | 1 |
| Castration-Resistant Prostate Carcinoma | 1 |
| Metastatic Prostate Adenocarcinoma With Neuroendocrine Differentiation | 1 |
| Metastatic Prostate Carcinoma | 1 |
| Endometrial Adenocarcinoma | 1 |
| Endometrial Mixed Cell Adenocarcinoma | 1 |
| Endometrial Serous Adenocarcinoma | 1 |
| Endometrial Undifferentiated Carcinoma | 1 |
| Advanced Malignant Solid Neoplasm | 1 |
| Metastatic Lung Non-Small Cell Carcinoma | 1 |
| Metastatic Lung Small Cell Carcinoma | 1 |
| Metastatic Pancreatic Adenocarcinoma | 1 |
| Fallopian Tube Undifferentiated Carcinoma | 1 |
| Ovarian Clear Cell Adenocarcinoma | 1 |
| Fallopian Tube Mucinous Adenocarcinoma | 1 |
| Ovarian Seromucinous Carcinoma | 1 |
| Platinum-Refractory Fallopian Tube Carcinoma | 1 |
| Platinum-Refractory Ovarian Carcinoma | 1 |
| Fallopian Tube Carcinoma | 1 |
| Ovarian Endometrioid Adenocarcinoma | 1 |
| Ovarian High Grade Serous Adenocarcinoma | 1 |
| Ovarian Serous Adenocarcinoma | 1 |
Sponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 7 |
| AstraZeneca | 2 |
| University Health Network, Toronto | 1 |
By country register
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Cediranib Maleate trials
How many clinical trials are testing Cediranib Maleate?
10 current trials in our Canada, Israel, Mexico, South Korea, Japan, Egypt, UK, USA, Germany, France, Spain and Austria registers name Cediranib Maleate (also registered as AZD2171) as a drug or biological intervention, as of the registry sync on 13 November 2026. Completed and withdrawn studies are not counted.
Are Cediranib Maleate trials recruiting patients?
Not at the moment. None of the 10 trials in our registers is recruiting; they are active but closed to enrolment, not yet open, or enrolling by invitation. Only the study team can confirm whether a patient is eligible.
Who sponsors Cediranib Maleate clinical trials?
National Cancer Institute (NCI) (7), AstraZeneca (2) and University Health Network, Toronto (1). The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Cediranib Maleate works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Cediranib Maleate works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Cediranib Maleate (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 13 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.